Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 8, 2022 4:05 PM EDTPrioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases
Plans to Begin Phase 2 Clinical Trial of Ciforadenant in Front Line Renal Cell Cancer (RCC) in Partnership with Kidney Cancer Consortium in Q3 2022
Pausing Start of Randomized Phase 2 Clinical Trial of Mupadolimab in Lung Cancer; Extends Cash Runway into Early 2024
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT
BURLINGAME, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Â Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a... More
